Home Dialysis Module Cases

Dialysis Prescription & Complications

HD Prescription, Vascular Access, Intradialytic Complications & First Dialysis Considerations

Prescription Adequacy Vascular Access Complications Disequilibrium

Quick Navigation

HD Prescription Adequacy (Kt/V, URR) Urgent Indications Vascular Access Intradialytic Complications Disequilibrium Syndrome First Dialysis

Hemodialysis Prescription Components

The HD prescription specifies all parameters needed to deliver safe and effective renal replacement therapy. Each element influences solute clearance, fluid removal, electrolyte management, and hemodynamic tolerance.

Core Prescription Parameters

Blood Flow Rate (Qb)

Range: 300–450 mL/min

Higher Qb maintains concentration gradients and reduces recirculation. The relationship with clearance is curvilinear—diminishing returns above ~400 mL/min due to membrane limitations. Must match vascular access capacity.

Dialysate Flow Rate (Qd)

Range: 500–800 mL/min

Counter-current flow maximizes concentration gradients throughout the dialyzer length. Standard 500 mL/min is adequate for most patients; rates >600–700 mL/min yield marginal improvements in small solute clearance.

Treatment Duration

Standard: 3–4 hours, 3x/week

Linear relationship with solute removal. Extended times improve phosphate clearance and allow gentler ultrafiltration rates (<10–13 mL/kg/hr).

Dialyzer Selection

Surface area: 1.0–2.5 m²

High-flux membranes improve beta-2 microglobulin clearance (11,800 Da) and reduce dialysis-related amyloidosis. High-flux is preferred for most patients.

Net Ultrafiltration

Range: 0.5–4.0 L/session

Based on interdialytic weight gain and dry weight target. UF rates >10–13 mL/kg/hr increase risk of intradialytic hypotension.

Anticoagulation

Standard: Heparin bolus + infusion

Prevents clotting in extracorporeal circuit. Adjust for bleeding risk. Citrate or saline flushes used when heparin is contraindicated.

Dialysate Electrolyte Composition

Electrolyte Typical Range Clinical Considerations
Sodium 137–140 mEq/L default; individualize Higher Na supports hemodynamic stability during UF but increases interdialytic thirst and weight gain. Below 138 lowers weight gain and BP slightly but increases IDH and cramps (Marshall 2024); avoid hypernatremic dialysate (KDIGO 2020)
Potassium 2–3 mEq/L (1 or 4 only by specific order) Individualize based on pre-dialysis serum K; rapid shifts may trigger arrhythmias. See Rule of 8 below
Calcium 2.5–3.0 mEq/L (1.25–1.50 mmol/L) (KDIGO 2017) Adjust for CKD-MBD status; patients on calcium-based binders may need lower dialysate Ca
Bicarbonate 32–40 mEq/L setting; total buffer (bicarbonate + acetate) ≤37 mEq/L for most patients Corrects metabolic acidosis; avoid overcorrection causing post-dialysis alkalosis. Acetate (or citrate) from the acid concentrate adds to the bicarbonate setting (Ashby 2019); higher dialysate bicarbonate was associated with higher mortality, HR 1.08 per 4 mEq/L (Tentori 2013)
Magnesium 1.0 mEq/L (0.5 mmol/L) Standard concentration; most patients lose magnesium during treatment at this level (Leenders 2018)
Glucose 100 mg/dL (standard) Prevents intradialytic hypoglycemia: glucose-free dialysate causes frequent, usually silent, hypoglycemia (Burmeister 2007), and 200 mg/dL adds no benefit (Raimann 2012). No meaningful osmotic effect at these concentrations; UF is pressure-driven (Locatelli 2015)

The “Rule of 8” for Dialysate Potassium — A Heuristic, Not a Safety Rule

Serum K+ + Dialysate K+ ≈ 7–8

This bedside shortcut has never been tested against patient outcomes. The documented version is the “rule of 7,” an informal algorithm advocated for decades (Pun 2018) whose origin is undocumented; no peer-reviewed source was found for a “rule of 8.” The rule does not limit potassium removal. Under a fixed sum, the serum-to-dialysate gradient rises by 2 mEq/L for every 1 mEq/L rise in serum K (rule of 8: gradient = 2 × serum K − 8), so removal speeds up as potassium rises. What the sum actually targets is an end-of-treatment K of about 3.5 (rule of 7) to 4.0 (rule of 8) mEq/L (Abuelo 2018).

Serum K = 4.0: 3K (the rule gives 4K, which has almost no outcome data; reserve 4K for K persistently below 3.5)
Serum K = 5.0: 3K (8 − 5 = 3; gradient 2 mEq/L)
Serum K = 5.5: 2K or 3K (8 − 5.5 = 2.5, a bath many units do not stock; 3K plus a binder is favored in AF)
Serum K = 6.0: 2K for this treatment (gradient 4 mEq/L); repeat pre-dialysis K at the next session
Below 2K is a deliberate order, not a default. Patients who had an in-unit cardiac arrest were about twice as likely to have been dialyzed against a 0K or 1K bath that day (17.1% vs 8.8%) (Karnik 2001). At serum K ≥6.5, or with ECG changes, treat as an emergency: the nephrologist sets the bath (2K, or 1K by deliberate order) with continuous cardiac monitoring and a potassium recheck. Avoid sub-2K baths in patients taking digoxin (Chan 2010). 0K is not a routine option.
Clinical Pearl: 2K and 3K are the evidence-supported working range: in 55,183 DOPPS patients, 3K versus 2K carried the same adjusted mortality (HR 0.96, 95% CI 0.91–1.01) (Karaboyas 2017). In atrial fibrillation, favor 3K; 3K versus 2K was associated with fewer new AF diagnoses (HR 0.87) (Hu 2023). Changing the bath by 1 mEq/L moves the next pre-dialysis K by only about 0.09 mEq/L (Karaboyas 2017), so chronic hyperkalemia needs diet, bowel, medication, binder, and treatment-time changes rather than a lower bath. About 70% of the intradialytic K fall rebounds within 6 hours (Ahmed 2001) — never replace potassium based on a post-dialysis value.

Clearance Formula

Clearance (K) = Blood Flow Rate (Qb) × Extraction Ratio

Extraction Ratio = (Cin − Cout) / Cin

Where Cin = arterial (inlet) blood concentration and Cout = venous (outlet) blood concentration. Clearance can never exceed Qb or Qd (whichever is lower). Higher extraction ratios indicate more efficient solute removal.

Dialysis Adequacy: Kt/V and URR

Kt/V (Fractional Clearance)

K = dialyzer clearance (mL/min)
t = treatment time (minutes)
V = urea distribution volume (mL)

HD target: Kt/V ≥ 1.2 per session

PD target: Weekly Kt/V ≥ 1.7

Single-pool vs. Equilibrated Kt/V: Single-pool assumes instantaneous equilibration and overestimates delivered dialysis. Equilibrated Kt/V accounts for urea rebound and is typically 10–15% lower.

URR (Urea Reduction Ratio)

URR = (Pre-BUN − Post-BUN) / Pre-BUN × 100%

Target: URR > 65%

Simpler calculation than Kt/V with similar clinical utility for monitoring adequacy.

Example: Pre-BUN 80, Post-BUN 20
URR = (80 − 20) / 80 × 100 = 75% (adequate)

Monthly Adequacy Monitoring

  • Kt/V measurement (target ≥1.2)
  • URR (target >65%)
  • Pre- and post-dialysis electrolytes and minerals
  • Hemoglobin/hematocrit (anemia management)
  • Phosphorus and PTH (mineral metabolism)
  • Albumin (nutritional status marker)

Urgent Dialysis Indications: AEIOU

When conservative management fails, urgent dialysis is indicated for life-threatening complications of kidney failure. The mnemonic AEIOU captures the major indications:

A

Acidosis

Severe metabolic acidosis (pH <7.1–7.2) refractory to bicarbonate therapy

E

Electrolytes

Refractory hyperkalemia (K >6.5 with ECG changes) unresponsive to medical management

I

Intoxication

Dialyzable toxins: methanol, ethylene glycol, lithium, salicylates, metformin

O

Overload

Volume overload with pulmonary edema refractory to diuretic therapy

U

Uremia

Uremic symptoms: encephalopathy, pericarditis, neuropathy, bleeding

High-Yield: Uremic pericarditis is an absolute indication for urgent dialysis. Uremic encephalopathy (asterixis, confusion, seizures) requires emergent initiation. Uremic bleeding responds to dialysis, desmopressin, and cryoprecipitate.

Vascular Access for Hemodialysis

The hierarchy of preferred access follows: AV Fistula > AV Graft > Tunneled Catheter > Temporary Catheter. Fistula First initiative targets ≥65% fistula prevalence in dialysis units.

AV Fistula (Gold Standard)

Construction: Direct artery-to-vein anastomosis (typically radial artery to cephalic vein)

Maturation: 6–12 weeks

Blood flow: 400–600+ mL/min

Advantages

  • Lowest infection rates
  • Superior longevity (10–15+ years)
  • Highest achievable Qb
  • Reduced thrombosis vs. grafts

Assessment

  • Bruit: Whooshing sound (turbulent flow) — normal finding
  • Thrill: Palpable vibration — normal finding
  • Loss of bruit/thrill: Suggests clotting or stenosis

AV Graft

Construction: Synthetic PTFE conduit connecting artery to vein

Maturation: 2–4 weeks

Advantages

  • Shorter maturation than fistula
  • Suitable when native vessels are inadequate

Disadvantages

  • Higher infection rates than fistulas
  • Increased thrombosis risk
  • Shorter functional lifespan
  • More prone to stenosis

Central Venous Catheters

Tunneled (Permcath): Dual-lumen, subcutaneous tunnel, Dacron cuff. Internal jugular preferred. Used as bridge therapy or when permanent access fails.

Temporary (Non-tunneled): For acute dialysis (<2–3 weeks). Internal jugular, femoral, or subclavian. Subclavian carries highest stenosis risk—avoid if future fistula planned.

Complications

  • Catheter-related bloodstream infections (~2.1 per 1,000 catheter-days)
  • Central venous stenosis/thrombosis
  • Mechanical dysfunction (fibrin sheath, kinking)

Vascular Access Complications

Complication Pathophysiology Clinical Features Management
Steal Syndrome AV access diverts excessive blood flow from distal extremity Digital ischemia, pain, numbness, coldness, tissue necrosis Access modification, banding, DRIL procedure, or closure in severe cases
Stenosis Neointimal hyperplasia at venous anastomosis or outflow Elevated venous pressures, prolonged bleeding, decreased Qb, arm swelling Angioplasty, stenting, or surgical revision
Thrombosis Usually secondary to underlying stenosis; low flow states Loss of thrill and bruit, inability to cannulate Thrombectomy (surgical or pharmacomechanical), address underlying stenosis
Infection Bacterial colonization; highest with catheters, lowest with fistulas Erythema, drainage, fever, bacteremia, sepsis Antibiotics; catheter exchange or removal; graft excision if abscess
High-Output Cardiac Failure Access flow >2 L/min increases cardiac output demand LVH, heart failure symptoms, pulmonary hypertension Access flow reduction (banding), revision, or closure
Aneurysm/Pseudoaneurysm Repeated cannulation weakens vessel wall Expanding pulsatile mass, risk of rupture Surgical repair; rotate cannulation sites (rope-ladder technique)

Intradialytic Complications

Intradialytic Hypotension (IDH) — Most Common (approximately 10–12% of sessions)

Frequency depends on the definition: pooled estimates are 10.1% of sessions by the EBPG definition and 11.6% by a nadir systolic BP below 90 mmHg (Kuipers 2019). A nadir below 90 mmHg, even without symptoms, carries the strongest association with mortality (Flythe 2015).

Pathophysiology

  1. UF removes fluid from intravascular compartment
  2. Vascular refill from interstitium cannot keep pace
  3. Despite total body fluid overload, circulating volume depletes
  4. Autonomic compensation impaired in uremia
  5. Warm dialysate and acetate cause peripheral vasodilation

Clinical Features

  • Symptomatic BP reduction
  • Cramping, nausea, vomiting
  • Dizziness, altered mental status
  • Muscle cramping (cellular dehydration)

Immediate Management

  1. Stop ultrafiltration (most effective initial step)
  2. Trendelenburg positioning (feet above heart)
  3. NS bolus 100–250 mL
  4. Hypertonic saline or mannitol (enhances plasma refilling)

Prevention Strategies

  • Accurate dry weight determination
  • UF rate <10–13 mL/kg/hr
  • Cool dialysate (35.5–36°C)
  • Routine sodium modeling/profiling is not recommended: associated with higher mortality in DOPPS, HR 1.36 (Dasgupta 2019); KDIGO aims for negative sodium balance during treatment (KDIGO 2020)
  • Hold antihypertensives pre-dialysis
  • Midodrine: short-term BP gains only in small studies (Prakash 2004) and an association with higher mortality in a matched cohort (Brunelli 2018); no outcome trial — reserve for refractory symptomatic IDH, by physician order
  • Extended treatment times
Key Concept — Vascular Refill: The rate of fluid mobilization from edematous tissues to the vascular compartment (typically 200–400 mL/hr) is the limiting factor. When UF exceeds refill capacity, intravascular depletion develops despite total body fluid excess. This explains why edematous patients still become hypotensive on dialysis.

Muscle Cramps

  • Mechanism: Rapid fluid shifts, electrolyte changes, cellular dehydration
  • Risk factors: Aggressive UF, large interdialytic weight gains, low Na dialysate
  • Management: Reduce UF rate, increase dialysate Na, stretch/massage, longer treatment times

Air Embolism

Life-threatening emergency. Air enters extracorporeal circuit through line disconnections, cracked tubing, or empty saline bag. Modern machines have air detectors, but vigilance is essential.
  • Symptoms: Sudden dyspnea, chest pain, cyanosis, cardiovascular collapse
  • Immediate management: Clamp venous line, place patient left lateral decubitus (Durant maneuver) and Trendelenburg, aspirate air from CVC if present, 100% O2

Hemolysis

Causes: Overheated dialysate, hypotonic dialysate, kinked blood lines, contaminated water supply (chloramine, copper), malfunctioning blood pump.
  • Signs: Port-wine colored blood in return line, back pain, chest tightness, hypotension, hyperkalemia
  • Management: Stop dialysis immediately, do NOT return blood (it contains free K from lysed cells), check dialysate composition and water quality

Dialysis Disequilibrium Syndrome (DDS)

Pathophysiology

Rapid removal of urea and other osmotically active solutes from blood during dialysis creates a transient osmotic gradient between plasma and the brain. The blood-brain barrier limits rapid equilibration, causing water to shift into brain cells.

  1. Rapid solute (urea) clearance from blood
  2. Blood osmolality drops quickly
  3. Brain retains idiogenic osmoles (organic osmolytes)
  4. Osmotic gradient drives water into brain tissue
  5. Cerebral edema develops

Clinical Manifestations

  • Mild: Headache, nausea, vomiting, restlessness
  • Moderate: Disorientation, blurred vision, muscle twitching
  • Severe: Seizures, obtundation, coma (rarely fatal)

Risk Factors

  • First dialysis treatments (highest risk)
  • Very high pre-dialysis BUN (>150 mg/dL)
  • Severe metabolic acidosis
  • Pediatric and elderly patients
  • Pre-existing CNS disease
  • Hyponatremia

Prevention Strategies

  • Shorter first treatments (2 hours, then gradually increase)
  • Lower blood flow rates initially (200 mL/min)
  • Target modest BUN reduction (<40% on first session)
  • Mannitol infusion (0.5–1 g/kg) to maintain plasma osmolality
  • Higher dialysate sodium (145–150 mEq/L)
  • Cool dialysate

Treatment

  • Stop dialysis or slow blood flow rate
  • IV mannitol (1 g/kg) or hypertonic saline (23.4%)
  • Benzodiazepines or phenytoin for seizures
  • CT head to exclude other causes (subdural hematoma, stroke)

First Dialysis in the Acutely Ill Patient

Initiating dialysis in a critically ill patient with severe uremia requires a careful approach to avoid disequilibrium syndrome and hemodynamic instability.

Key Principles

Parameter First Treatment Subsequent Treatments Rationale
Duration 2 hours Increase by 30–60 min each session to target 3–4 hrs Limits osmolality shift, reduces DDS risk
Blood flow 200 mL/min Increase by 50 mL/min each session to 300–400 Slower clearance rate prevents rapid osmotic shifts
BUN reduction target <30–40% Normal adequacy targets Aggressive reduction in severely uremic patients causes DDS
Dialysate Na 145–150 mEq/L Standard (140 mEq/L) Maintains plasma osmolality during urea removal
UF goal Modest (1–2 L max) Based on fluid status Hemodynamic instability is common; prioritize solute clearance over volume removal initially
Mannitol Consider 0.5–1 g/kg IV Usually not needed Counteracts osmotic gradient; prevents cerebral edema
Frequency Daily or every other day 3x/week when stable Frequent short treatments are safer than infrequent long ones in the initial period
Clinical Pearl: For patients with BUN >150 mg/dL, consider CRRT (continuous renal replacement therapy) or SLED (sustained low-efficiency dialysis) as alternatives for the initial treatment. These modalities provide gentler solute clearance over extended periods and are better tolerated hemodynamically in ICU patients.
Critical Reminder: Always assess for and address hyperkalemia before and during the first dialysis session. Potassium-related cardiac arrest is the most immediately life-threatening complication in patients presenting with severe AKI or ESKD. Obtain a 12-lead ECG and ensure continuous telemetry monitoring.

References

  1. Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 5th ed. Wolters Kluwer; 2015.
  2. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. Am J Kidney Dis. 2015;66(5):884-930. PubMed
  3. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164. PubMed
  4. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int. 2011;79(2):250-257. PubMed
  5. Zepeda-Orozco D, Quigley R. Dialysis disequilibrium syndrome. Pediatr Nephrol. 2012;27(12):2205-2211. PubMed
  6. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2020;75(1 Suppl 1):A6-A7. PubMed
  7. Rayner HC, Zepel L, Fuller DS, et al. Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2014;64(1):86-94. PubMed
  8. Chou JA, Streja E, Nguyen DV, et al. Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrol Dial Transplant. 2018;33(1):149-159. PubMed
  9. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol. 2004;15(2):477-486. PubMed
  10. Basile C, Pisano A, Lisi P, et al. High versus low dialysate sodium concentration in chronic haemodialysis patients: a systematic review and meta-analysis. Nephrol Dial Transplant. 2016;31(4):548-563. PubMed
  11. Pun PH. Dialysate potassium concentration: should mass balance trump electrophysiology? Semin Dial. 2018;31(6):569-575. PubMed
  12. Abuelo JG. Treatment of severe hyperkalemia: confronting 4 fallacies. Kidney Int Rep. 2018;3(1):47-55. PubMed
  13. Karaboyas A, Zee J, Brunelli SM, et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2017;69(2):266-277. PubMed
  14. Karnik JA, Young BS, Lew NL, et al. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350-357. PubMed
  15. Hu A, Liu S, Montez-Rath ME, et al. Associations of serum and dialysate potassium concentrations with incident atrial fibrillation in a cohort study of older US persons initiating hemodialysis for kidney failure. Kidney Int Rep. 2023;8(2):305-316. PubMed
  16. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010;21(9):1550-1559. PubMed
  17. Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial. 2001;14(5):348-356. PubMed
  18. Kuipers J, Verboom LM, Ipema KJR, et al. The prevalence of intradialytic hypotension in patients on conventional hemodialysis: a systematic review with meta-analysis. Am J Nephrol. 2019;49(6):497-506. PubMed
  19. Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. 2015;26(3):724-734. PubMed
  20. Marshall MR, Wang MY, Vandal AC, Dunlop JL. Low dialysate sodium levels for chronic haemodialysis. Cochrane Database Syst Rev. 2024;11:CD011204. PubMed
  21. Flythe JE, Chang TI, Gallagher MP, et al. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(5):861-876. PubMed
  22. KDIGO CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. PubMed
  23. Ashby D, Borman N, Burton J, et al. Renal Association clinical practice guideline on haemodialysis. BMC Nephrol. 2019;20(1):379. PubMed
  24. Tentori F, Karaboyas A, Robinson BM, et al. Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2013;62(4):738-746. PubMed
  25. Leenders NHJ, van Ittersum FJ, Hoekstra T, Hoenderop JGJ, Vervloet MG. Routine hemodialysis induces a decline in plasma magnesium concentration in most patients: a prospective observational cohort study. Sci Rep. 2018;8(1):10256. PubMed
  26. Burmeister JE, Scapini A, da Rosa Miltersteiner D, da Costa MG, Campos BM. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis. Nephrol Dial Transplant. 2007;22(4):1184-1189. PubMed
  27. Raimann JG, Kruse A, Thijssen S, et al. Metabolic effects of dialyzate glucose in chronic hemodialysis: results from a prospective, randomized crossover trial. Nephrol Dial Transplant. 2012;27(4):1559-1568. PubMed
  28. Locatelli F, La Milia V, Violo L, Del Vecchio L, Di Filippo S. Optimizing haemodialysate composition. Clin Kidney J. 2015;8(5):580-589. PubMed
  29. Dasgupta I, Thomas GN, Clarke J, et al. Associations between hemodialysis facility practices to manage fluid volume and intradialytic hypotension and patient outcomes. Clin J Am Soc Nephrol. 2019;14(3):385-393. PubMed
  30. Prakash S, Garg AX, Heidenheim AP, House AA. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. Nephrol Dial Transplant. 2004;19(10):2553-2558. PubMed
  31. Brunelli SM, Cohen DE, Marlowe G, Van Wyck D. The impact of midodrine on outcomes in patients with intradialytic hypotension. Am J Nephrol. 2018;48(5):381-388. PubMed

Andrew Bland, MD, FACP, FAAP | University of Dubuque PA Program | Urine Nephrology Now

© 2025 | For educational purposes only

Also on this topic

The same subject at other levels of depth.